Botulism - Pipeline Review, H1 2020

January 2020 | 36 pages | ID: B7619720AAEEN
Global Markets Direct

Abstracts

Botulism - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Botulism - Pipeline Review, H1 2020, provides an overview of the Botulism (Infectious Disease) pipeline landscape.

Botulism is a rare but serious illness. The cause is a toxin (poison) made by a bacterium called Clostridium botulinum. It occurs naturally in soil. Food borne botulism comes from eating foods contaminated with the toxin. Symptoms include double or blurred vision, drooping eyelids, slurred speech, difficulty swallowing, dry mouth, and muscle weakness. Treatment may include antitoxins, intensive medical care, or surgery of infected wounds.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Botulism - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Botulism (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Botulism (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Botulism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Preclinical stages are 4 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 3 and 1 molecules, respectively.

Botulism (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Botulism (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Botulism (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Botulism (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Botulism (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Botulism (Infectious Disease)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Botulism (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Botulism (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Botulism - Overview
Botulism - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Botulism - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Botulism - Companies Involved in Therapeutics Development
CytoDel Inc
Hawaii Biotech Inc
Inventox Inc
Shield Pharma LLC
Botulism - Drug Profiles
bithionol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
botulinum vaccine [serogroups A, A1, B and B1] - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
botulism [serotype C] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
botulism [serotypes A, B, E] (trivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cyto-111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit Botulinum Neurotoxin Type A for Botulism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit Botulinum Neurotoxin E for Botulism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Botulinum Neurotoxin Type A for Botulism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Botulinum Toxin for Botulism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Botulism - Dormant Projects
Botulism - Discontinued Products
Botulism - Product Development Milestones
Featured News & Press Releases
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Botulism, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Botulism - Pipeline by CytoDel Inc, H1 2020
Botulism - Pipeline by Hawaii Biotech Inc, H1 2020
Botulism - Pipeline by Inventox Inc, H1 2020
Botulism - Pipeline by Shield Pharma LLC, H1 2020
Botulism - Dormant Projects, H1 2020
Botulism - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Botulism, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

CytoDel Inc
Hawaii Biotech Inc
Inventox Inc
Shield Pharma LLC